Adrian Bot, MD, PhD

Adrian Bot, MD, PhD

Company: Capstan Therapeutics

Job title: Chief Scientific Officer and Executive Vice President, R&D


Towards Next Generation CAR Therapy Including In Vivo Programming of Immune Cells & Non-Oncology Indications 5:00 pm

Development of first wave ex vivo manufactured autologous CAR-T cell products for B-cell malignancies yielded invaluable lessons, paving the way to next generation therapies Key opportunities to expand the footprint of this treatment modality include design and development of transformative off-the-shelf therapies including in vivo CARs, as well as translation of this technology to non-oncology…Read more

day: Day Two

Workshop A: In Vivo Production of Functional CAR-T Cells by mRNA Targeted Lipid Nanoparticles 9:00 am

Targeted lipid nanoparticles can effectively reprogramme T-cells in vivo to express a CAR CAR-T cells produced in this manner are functional and can ameliorate pathologyRead more

day: Workshop - Track A - Morning

Industry Leaders’ Fireside Chat – Setting a Trailblazing Fire to the Cell Therapy Field with Next Generation Approaches 9:00 am

An executive panel discussion from the industry leaders of the field to set the scene on next generation CAR-TCR therapies. Ask your questions live to understand the expert’s thoughts on key topics including: Successes and hurdles to date: T-cell therapy translation to solid tumours, non-oncologic disorders and off-the-shelf (ex vivo and in vivo) T-cell engineering…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.